Dr. Matthew Weinstock joins Novel Biotechnology Inc as CTO
Novel Biotechnology Inc., a biotech company developing new solutions for plasmid DNA manufacturing – a critical starting material for gene therapy, cell engineering, mRNA therapy and vaccine applications – is pleased to welcome Matthew Weinstock, PhD as Chief Technology Officer.
Dr. Weinstock is an accomplished biotech executive with experience working in both start-up and growth-stage companies. His technical expertise spans protein engineering, drug discovery, advanced biomanufacturing, and synthetic biology. His efforts have led to technologies that have been successfully commercialized or have resulted in technology development partnerships with top-10 pharma companies.
Prior to joining Novel Biotechnology, Dr. Weinstock served as Chief Technology Officer at Absci Corporation, a publicly traded biotech company developing advanced technologies for drug discovery and biomanufacturing, where he led a multi-department scientific organization of around 200 employees. Prior to Absci, Dr. Weinstock was employed at the synthetic biology firm Synthetic Genomics, Inc., where he was a program leader in the R&D group of Dr. Daniel Gibson.
Dr. Weinstock has a PhD in Biochemistry from the University of Utah School of Medicine where he was part of a group focused on the advancement of mirror-image display technologies to discover D-peptide therapeutics against emerging infectious diseases.